# Benitec Biopharma Inc.: Form 10-K/A for the period ended Jun 30, 2025

- Company: [Benitec Biopharma Inc.](/companies/bntc.md) (CIK 1808898)
- Form: 10-K/A
- Filed: 2026-03-20
- Accepted by EDGAR: Mar 20, 2026, 16:03 ET
- Period: 2025-06-30
- Accession: 0001193125-26-117604
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526117604/d226768d10ka.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1808898/000119312526117604/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2025-04-01 to 2025-06-30 | $2.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months, 2024-07-01 to 2025-06-30 | $18.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2025-04-01 to 2025-06-30 | −$9.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2024-07-01 to 2025-06-30 | −$41.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2025-04-01 to 2025-06-30 | −$8.8m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2024-07-01 to 2025-06-30 | −$37.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-04-01 to 2025-06-30 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2024-07-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-04-01 to 2025-06-30 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2024-07-01 to 2025-06-30 | −$1.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-04-01 to 2025-06-30 | 41,161,259 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months, 2024-07-01 to 2025-06-30 | 36,209,271 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-07-01 to 2025-06-30 | −$23.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-07-01 to 2025-06-30 | $18.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-06-30 | $97.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-06-30 | $98.5m | us-gaap:AssetsCurrent |
| Total assets | at 2025-06-30 | $99.6m | us-gaap:Assets |
| Current liabilities | at 2025-06-30 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-06-30 | $2.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-06-30 | $97.3m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1808898/000119312526117604/d226768d10ka.htm

Filed Mar 20, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-117604. Last ingested by Listed: Nov 14, 2026, 11:28 ET. No prices; not investment advice.
